Astellas Pharma Broadens Drug R&D Scope
This article was originally published in PharmAsia News
Astellas Pharma will place its priority on patent drug R&D and has identified six therapeutic areas to concentrate on: organ transplantation immunosuppressive/inflammation, urology, infectious disease, central nervous system/pain, diabetes and oncology. Last year, Astellas China concentrated mainly on transplantation immunosuppressive and urinary diseases, chalking up a 46 percent increase in sales. However, key immunosuppressive product Prograf (tacrolimus), which contributed half its total revenue, saw below-industry-average performance. Analysts observe that Astellas has to extend its focus from organ transplantation drugs to other fields due to restrictions imposed by China's Organ Transplantation Legislation and the small domestic market demand. (Click here for more - Chinese Language)
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.